Granzyme B
Ultrasensitive Immunoassay
Rules-Based Medicine’s (RBM) internally developed and manufactured ultrasensitive immunoassay to Granzyme B based on the Simoa® bead technology can accurately quantitate sub-pg/mL levels of granzyme B in human plasma and serum. The Simoa Granzyme B assay is a valuable clinical research tool for pharmacodynamic analysis of several diseases, including autoimmune skin diseases (lupus, psoriasis), rheumatoid arthritis, multiple sclerosis, viral infections, and others.
Granzyme B is a serine protease produced by cytotoxic T lymphocytes, natural killer cells, and at lower levels by various cell types: mast cells, macrophages, plasmatoid dendritic cells, and others. It is reported to be the most potent of the human granzymes (there are 5 in total: A, B, H, K, and M). Its mechanism of cell death involves cleaving proteins at the aspartic acid residues, and it can also directly activate the Bcl-2 and caspase pathways. Other mechanisms of cell death activation have also been described. While normal healthy individuals have circulating granzyme B, elevated levels in plasma are linked to several diseases, including autoimmune skin diseases (lupus, psoriasis), rheumatoid arthritis, multiple sclerosis, viral infections, and others.
Swiss-Prot Accession Number: P10144
Alternate names for this biomarker include:
C11, CTLA-1, Cathepsin G-like 1, CTSGL1, Cytotoxic T-lymphocyte proteinase 2, Lymphocyte protease, Fragmentin-2, Granzyme-2, Human lymphocyte protein, HLP, SECT, T-cell serine protease 1-3E
| Biomarker | LLOQ* (Serum and Plasma) |
LLOQ* (Undiluted Samples) |
Volume Required | |
|---|---|---|---|---|
| Serum or plasma | Other fluids** | |||
| Granzyme B | 0.30 pg/mL | 0.075 pg/mL | 100 µL | 150 µL |
* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.
** Cerebrospinal fluid, urine, tissue culture supernatants, bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.
All assay services are performed in our CLIA-certified laboratory.
Intended for Research Use Only.